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Abstract In this work, the usefulness of capillary electro-
phoresis–electrospray ionization time-of-flight–mass spec-
trometry for the analysis of biopharmaceuticals was studied.
Noncovalently bound capillary coatings consisting of
Polybrene-poly(vinyl sulfonic acid) or Polybrene-dextran
sulfate-Polybrene were used to minimize protein and peptide
adsorption, and achieve good separation efficiencies. The
potential of the capillary electrophoresis-mass spectrometry
(CE-MS) system to characterize degradation products was
investigated by analyzing samples of the drugs, recombinant
human growth hormone (rhGH) and oxytocin, which had
been subjected to prolonged storage, heat exposure, and/or
differentpHvalues.Modificationscouldbeassignedbasedon
accurate masses as obtained with time-of-flight–mass spec-
trometry (TOF-MS) and migration times with respect to the
parent compound. For heat-exposed rhGH, oxidations, sulfo-
nate formation, and deamidations were observed. Oxytocin
showedstrongdeamidation(upto40%)uponheatexposureat
low pH, whereas at medium and high pH, mainly dimer
(>10%) and trisulfide formation (6–7%) occurred. Recombi-
nant human interferon-β-1a (rhIFN-β) was used to evaluate
the capability of the CE-MS method to assess glycan
heterogeneity of pharmaceutical proteins. Analysis of this N-
glycosylated protein revealed a cluster of resolved peaks
which appeared to be caused by at least ten glycoforms
differing merely in sialic acid and hexose N-acetylhexos-
amine composition. Based on the relative peak area
(assuming an equimolar response per glycoform), a quanti-
tative profile could be derived with the disialytated bianten-
nary glycoform as most abundant (52%). Such a profile may
be useful for in-process and quality control of rhIFN-β
batches. It is concluded that the separation power provided
by combined capillary electrophoresis and TOF-MS allows
discrimination of highly related protein species.
Keywords Biopharmaceuticals.Capillary electrophoresis.
Electrospray ionization.Mass spectrometry.Noncovalent
coatings
Introduction
With efficient methodologies available in biotechnology
today, increasing numbers of recombinantly manufactured
pharmaceutical peptides and proteins are being commer-
cialized [1, 2]. The assessment of biopharmaceutical quality
in terms of identity, content, and purity is an important
issue during manufacturing. The biotechnological produc-
tion process may show variability, which can introduce
product diversity, isoforms, and closely related degradation
products [3, 4]. With the appearance of biosimilars, i.e.,
attempted copies of the original biopharmaceutical [4], the
demand for extensive characterization of therapeutic pro-
teins and peptides has even further increased. The variabil-
ity and stability between biosimilar and originator product
might differ even more significantly than between batches
of the same product. Clearly, there is an increasing demand
for suitable analytical methods that allow not only protein
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DOI 10.1007/s00216-011-4738-4and peptide identification, but also the separation and
quantificationofimpuritiesandpossibledegradationproducts.
Capillary electrophoresis-mass spectrometry (CE-MS)
provides the high separation efficiency and mass-selective
detection [5, 6] that can be very useful for biopharmaceut-
ical product characterization. Many protein modifications,
like glycosylation and deamidation, may involve changes
of net charge of a protein and, thus, also of its electropho-
retic mobility. As capillary electrophoresis (CE) has the
intrinsic capacity to produce narrow peaks, it shows good
potential for the separation of a variety of protein
modifications in a single run. Mass spectrometry (MS)
detection of high mass accuracy and resolution, such as
provided by time-of-flight (TOF) instruments can yield
accurate information on the molecular weight of analyzed
proteins species. CE-MS is most commonly carried out
applying electrospray ionization (ESI) using a sheath liquid
interface, which is relatively robust and easy to implement.
The sheath liquid composition and flow rate can be
optimized to enhance protein signal intensities [7, 8]. So
far, the application of sheath liquid CE-MS for the analysis
of biopharmaceuticals has been quite limited. Staub et al.
developed a CE-TOF-MS method to distinguish natural
human growth hormone (hGH) from recombinant hGH [9],
and Catai et al. showed the feasibility of CE-ion trap-MS
for the determination of some degradation products in hGH
after heat exposure and prolonged storage [10, 11]. Neusüß
et al. and Sanz-Nebot et al. demonstrated the usefulness of
CE-TOF-MS for the glycoform characterization of erythro-
poietin [12–16].
The tendencyofproteinmolecules toadsorbtofused-silica
may result in deterioration of CE separation efficiencies. In
order to prevent adverse interactions, it is a common strategy
to coat the internal wall surfaces with agents that minimize
protein adsorption [17, 18]. Two general coating strategies
can be discerned in CE: dynamic and static coating [19].
Dynamic coating agents are continuously present in the BGE
and reduce protein adsorption by reversibly binding to
adsorption sites on the silica surface. For CE-MS, a
disadvantage of this type of coating is that coating agents
may enter the ion source and, thereby, can result in
ionization suppression of the analyte and contamination of
the mass spectrometer. In order to prevent MS detection
interferences, static coatings have to be used. These coatings
are permanently attached to the capillary surface by
adsorption or by covalent coating involving silane chemistry
and polymerization schemes. The former capillary coatings
can be produced simply by flushing the capillary with
solutions of highly adsorptive agents. Very stable and
uniform adsorbed coatings can be produced by applying
multiple layers of oppositely charged polymers, as indicated
for the first time by Katayama et al. [20, 21]a n d
demonstrated by others subsequently [22–29].
Over the last years, we have studied and shown the
usefulness of a bilayer coating of Polybrene-poly(vinyl
sulfonic acid) (PB-PVS) and a triple layer coating of
Polybrene-dextran sulfate-Polybrene (PB-DS-PB) for the
CE-UV and CE-MS analysis of peptides and proteins
[10, 11, 30–33]. The negatively charged PB-PVS coating
was used in combination with a background electrolyte
( B G E )o fm e d i u mo rh i g hp Hf o rt h ea n a l y s i so fa c i d i c
peptides and proteins [10, 11, 30, 31], whereas for basic
proteins, the positively charged PB-DS-PB coating was
used in combination with a low-pH BGE [32, 33]. The
multilayer coatings exhibit a pH-independent and highly
reproducible EOF and effectively prevent protein adsorp-
tion [34], resulting in efficient protein separations. In
addition, these coatings show very good compatibility
with electrospray ionization–mass spectrometry (ESI-MS)
detection [31, 32]. As a result, both CE-MS systems
showed good performance for intact protein analysis
yielding RSDs for migration time and peak area within
2% and 10%, respectively [10, 11, 32, 33]. Linear
relationships between protein concentration and peak area
were achieved, and detection limits as low as 11 nM could
be obtained [32].
In the study presented here, the performance and
usefulness of CE-MS systems employing PB-PVS and
PB-DS-PB coated capillaries for the characterization of
biopharmaceuticals was investigated. Representative sam-
ples of the drugs, recombinant human growth hormone
(rhGH, 22 kDa, pI 5.1), recombinant human interferon-β-
1a (rhIFN-β, 23 kDa, pI 9.6), and oxytocin (1 kDa, pI 8.6)
were used for testing. The potential of the CE-MS systems
to separate and identify degradation products resulting from
heat stress and/or prolonged storage of rhGH and oxytocin
was studied. In addition, rhIFN-β was analyzed to evaluate
the capability of the PB-DS-PB CE-TOF-MS method to
assess the glycoform heterogeneity of a pharmaceutical
protein. Some attention was paid to optimization of
separation and detection conditions, but emphasis was on
the type of information on the sample composition that can
be obtained with CE-TOF-MS.
Materials and methods
Chemicals
Polybrene (hexadimethrine bromide, PB; average Mw
15,000), dextran sulfate (DS; average Mw>500,000) sodium
salt, 25% (w/v) poly (vinyl sulfonic acid) (PVS; average Mw
4,000–6,000), isopropanol, and acetonitrile were purchased
from Sigma Aldrich (Steinheim, Germany). Acetic acid,
formic acid, and 25% (v/v) ammonium hydroxide were
obtained from Merck (Darmstadt, Germany). The ammonium
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i d et o7 5m Ma n da d j u s t i n gt h ep Ht o8 . 5w i t h1 %( v/v)
formic acid in deionized water. Acetic acid BGEs were
prepared by diluting acetic acid to the desired concentra-
tion with deionized water and adjusted to the appropriate
pH with 1% (v/v) ammonium hydroxide in deionized
water.
A solution of rhGH had been prepared previously by
dissolving somatropin CRS (European Directorate for the
Quality of Medicines, Strasbourg, France) in 30 mM Tris
phosphate (pH 7.5) to a concentration of 1.5 mg/mL. An
aliquot of this sample was incubated at 40°C for 24 h and
subsequently had been stored for 12 months at −18°C.
Oxytocin acetate powder (Sigma Aldrich, Zwijndrecht, The
Netherlands) had been dissolved previously in 50 mM
phosphate buffer with a pH of 2.0, 4.5, 7.0, and 9.0 to a
final concentration of 50 μg/mL. Aliquots of these
solutions had been subsequently exposed to 70°C for 64 h
and then were stored at 4°C until analysis. Bulk rhIFN-β-
1a was supplied by Biogen Idec Inc. (Cambridge, MA,
USA) as a 0.27 mg/ml solution in 100 mM sodium
phosphate buffer and 200 mM sodium chloride at
pH 7.2. Reformulated rhIFN β-1a was produced by
dialysis of bulk rhIFN-β-1a with a 3.5-kDa molecular
weight cut-off (MWCO) Slide-A-Lyzer Cassette (Perbio
Science, Etten-Leur, The Netherlands) against a com-
mercially used formulation containing 20 mM sodium
acetate buffer, 150 mM L-arginine monohydrochloride
and 0.04 mM Tween 20 (Sigma Aldrich, Zwijndrecht,
The Netherlands) at pH 4.8 and subsequent filtration
through a 0.22-μm polyethersulfone membrane
(Millipore, Amsterdam, The Netherlands). This solution
was stored at 4°C until analysis. Prior to CE-MS analysis,
the formulation buffer was exchanged for water using a
MWCO filter of 3 kDa. The final solution had a rhIFN-β
concentration of 450 μg/mL.
CE system
The experiments were carried out on a P/ACE MDQ
capillary electrophoresis instrument (Beckman Coulter,
Brea, CA, USA). Fused-silica capillaries were from Poly-
micro Technologies (Phoenix, AZ, USA) having a total
length of 80 cm and an internal diameter of 50 μm.
Hydrodynamic injections were performed at 1 psi for 12 s
(i.e., 1% of the total capillary volume). The separation
voltage was 30 kV (PB-PVS coating) or −30 kV (PB-DS-
PB coating), and the capillary temperature was 20°C. New
fused-silica capillaries were rinsed with 1 M NaOH for
30 min at 20 psi and water for 15 min at 20 psi. After this
treatment, capillaries were coated with either a PB-PVS
coating or a PB-DS-PB coating using the procedures
described below.
Capillary coating
PB was dissolved in deionized water to a final concentration
of 10 % (w/v), and DS was dissolved to 0.5 % (w/v)w i t h
deionized water. PVS was diluted in deionized water to 1%
(w/v). The coating agents were filtered over a 0.45-μmf i l t e r
type HA (Millipore, Molsheim, France) prior to use. The
PB-PVS coating was applied by subsequently rinsing
30 min with 10% (w/v) PB solution at 5 psi, 10 min with
deionized water at 10 psi, 30 min with 1% (v/v)P V S
solution at 5 psi, and 10 min with deionized water at
10 psi. The PB-DS-PB coating was applied by subse-
quently rinsing 30 min with 10% (w/v) PB solution at
5 psi, 10 min with deionized water at 10 psi, 45 min with
0.5% (w/v) DS solution at 5 psi, 10 min with deionized
water at 10 psi, 30 min with 10% (w/v) PB solution at
5 psi. After the final coating agent flushing step, the
capillary was rinsed 10 min with deionized water at 10 psi.
The capillary was then ready for CE analysis with the
BGE of choice. Between runs, coated capillaries were
flushed with BGE for 3 min at 10 psi. Overnight,
capillaries were filled with BGE, and tips were immersed
in vials with BGE.
Mass spectrometry
MS was performed using a micrOTOF orthogonal-
accelerated TOF mass spectrometer (Bruker Daltonics,
Bremen, Germany). Source and transfer parameters were
optimized by direct infusion of an ESI tuning mix (Agilent
Technologies, Waldbronn, Germany). CE-MS coupling was
realized by a co-axial sheath liquid interface (Agilent
Technologies, Waldbronn, Germany). For the analysis of
rhGH, the sheath liquid was acetonitrile–water–formic acid
(75/25/5, v/v/v) at a flow rate of 4 μL/min. Sheath liquids
(2 μL/min) for oxytocin and rhIFN-β analyses were
isopropanol–water–acetic acid (75/25/0.1, v/v/v) and iso-
propanol–water–acetic acid (25/75/0.5, v/v/v), respectively.
Sheath liquid was delivered by a 2.5-mL gas-tight syringe
(Hamilton, Reno, NV, USA) using a syringe pump of Cole-
Parmer (Vernon Hill, IL, USA). The following optimized
spray conditions were used: dry gas temperature, 180°C;
nitrogen flow, 4 L/min; and nebulizer pressure, 0.4 bar.
Electrospray in positive ionization mode was achieved
using an ESI voltage of −4.5 kV. To assure proper ion
transfer, the analysis of rhGH and rh IFN-β were performed
with a capillary exit and skimmer voltage of 250 and 83 V,
respectively. For the analysis of oxytocin, these voltages
were set at to 200 and 50 V, respectively. CE-MS data were
analyzed using Bruker Daltonics Data Analysis software.
Molecular weight determinations of proteins were per-
formed using the “Charge Deconvolution” utility of the
DataAnalysis software.
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Recombinant human growth hormone
rhGH is a therapeutic protein used in the treatment of retarded
growth and dwarfism caused by the inadequate production of
the hormone during the growth period. The monograph of
rhGH in the European Pharmacopoeia (Ph. Eur.) includes a
CE method using bare fused-silica capillaries for detection of
chargevariants[35]. Catai et al. proposed the use of PB-PVS
coated capillaries for rhGH analysis by CE in order to
improve the method’s repeatability, resolution, and efficiency
[11]. Furthermore, an MS-compatible method was developed
using a volatile BGE of ammonium formate [10, 11].
However, the resolution and mass accuracy of the used ion
trap mass spectrometer were not sufficient to unambiguously
assign rhGH degradation products. Here, we study the
potential of CE-TOF-MS with PB-PVS coated capillaries
for the characterization of a heat-exposed and stored rhGH
sample.
First, a solution of 1.5 mg/mL rhGH (somatropin CRS)
was analyzed by CE-TOF-MS using a BGE of 75
ammonium formate (pH 8.5). Under these conditions, both
the protein (pI 5.1) and the PB-PVS coated capillary wall
are negatively charged, preventing protein adsorption. A
sheath liquid of low pH was used to allow efficient positive
ESI. A narrow symmetric peak (N, 105,000) was obtained
for rhGH at a migration time of approximately 11.5 min
(Fig. 1a, peak 0). Deconvolution of the mass spectrum
obtained in the apex of the peak (Fig. 1b) revealed a protein
molecular weight of 22123.9 Da, which well agrees with
the expected molecular weight for rhGH. Remarkably, the
mass spectrum seems to comprise two charge state
distributions. This might be explained by partial unfolding
of the protein during ESI, which leads to increased charging
and a shift of the distribution to lower m/z values [36]. Next
to hGH, a small additional peak at 10.2 min was detected.
Its mass spectrum shows major signals at m/z 804.3 and
986.4, but no typical protein charge state distribution. The
sample component could not be identified, but we presume
it is a low-molecular-weight compound. Next, an aqueous
solution of rhGH CRS (1.5 mg/mL) that was exposed to heat
(40 °C) for 24 h and then had been stored for 1 year at −18°C
was analyzed using the PB-PVS CE-TOF-MS system. The
resulting base peak electropherogram (BPE) shows that
several degradation products have been formed (Fig. 1c). As
these products were not detected during the analysis of the
CRS compound, we conclude that the applied CE-MS
conditions do not cause interfering artifacts. That is, the
observed extra compounds originate from heat exposure and/
or prolonged storage. The unknown impurity was again
observed at 10.2 min. The protein mass spectra obtained for
the peaks between 11.5 and 13.0 min are depicted in Fig. 1d,
yielding deconvoluted masses of 22156.1, 22157.0, 22252.3,
and 22253.3 Da for peaks 1 to 4, respectively. Remarkably,
no unmodified rhGH (22124 Da) was found in the sample,
although the main degradation product (peak 1) had virtually
the same migration time as rhGH CRS (11.6 min). The
observed mass difference of 32 Da for peak 1 with respect to
rhGH CRS suggests the main degradation product to be
double oxidized rhGH. Oxidation of methionine residues is a
common modification observed for rhGH [37, 38]. The gain
of two oxygen atoms will hardly affect the electrophoretic
mobility of the protein, as the oxidation induces no change
in the protein charge and only a very small relative change in
protein mass. The compound migrating at 11.8 min (peak 2)
is clearly separated from the oxidized rhGH (peak 1) and
differs only by 0.9 Da in mass. Most probably, peak 2 is
caused by rhGH that is oxidized (twice) as well as
deamidated (once). Deamidation is a common protein
degradation [39] that results in a small change of protein
molecular mass (+0.984 Da), but, at pH 8.5, also in a net
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Fig. 1 CE-TOF-MSofa, b rhGH CRS and c, d heat-exposed and stored
rhGH CRS using a PB-PVS coated capillary. a, c BPE (m/z 1,500–
3,000), the asterisk indicates an unknown non-proteinaceous unknown
compound. b, d Mass spectra obtained in the apex of the indicated peaks.
Conditions: BGE, 75 ammonium formate (pH 8.5); sheath liquid,
acetonitrile–water–formic acid (75/25/5, v/v/v)a t4μL/min. Sample
preparation and other conditions, see Materials and methods section
298 R. Haselberg et al.increase of one negative charge of the protein due to the
formation of an aspartic acid residue. As a consequence, the
protein’s electrophoretic mobility changes significantly. The
molecular mass of the degradation product migrating at
12.2 min (peak 3) is 128 Da higher than rhGH CRS. As this
compound migrates after the deamidated product (peak 2), it
most likely has gained at least two negative charges with
respect to rhGH. Therefore, the mass difference of 128 Da
could be explained by the formation of two sulfonic acid
groups from a protein disulfide bridge in addition to the
double methionine oxidation described above. This would
explainthegainofnegativecharge(twosulfonategroups)and
molecular mass (eight oxygen atoms) leading to the observed
electrophoretic mobility and molecular weight. Disulfide
bridge breakage and oxidation has been described for bovine
growth hormone [40], but to our knowledge, not for rhGH.
Considering its molecular mass (22253.3 Da) and migration
time (12.5 min), the component causing peak 4 most
probably is the singly deamidated form of the sulfonated/
oxidized product (peak 3). So, from the CE-TOF-MS results,
it can be concluded that exposure of rhGH CRS in water to
mild heat followed by prolonged storage can lead to
oxidation of the protein accompanied by deamidation.
From our present results and those reported previously
[10, 11], we can conclude that our CE-MS method with PB-
PVS coated capillaries is beneficial as it provides faster and
more efficient and reproducible separations of rhGH than
the Ph. Eur. method, which employs bare fused-silica
capillaries. In addition, the use of TOF-MS detection adds
important selectivity, which enhances the reliability of the
methodprovidingadditionalseparation.For example,peaks 1
and 3 in Fig. 1c would erroneously have been assigned to
unmodified rhGH and a bisdeamidated product, respectively,
when using CE-UV method of the Ph. Eur.
Oxytocin
Oxytocin is a nonapeptide hormone drug containing an
internal disulfide bridge, w h i c hi su s e dt oi n d u c eo r
stimulate labor and to prevent post-partum hemorrhage. It
was demonstrated that oxytocin is susceptible to pH-
dependent degradation at elevated temperatures [41].
Oxytocin itself has been analyzed before with CE-UV
[42] and CE-MS [43], however, CE-MS characterization of
degradation products has not been reported. Here, we
investigated the possibility of CE-TOF-MS to reveal the
composition of heat-stressed samples of oxytocin. Oxytocin
solutions of pH 2.0, 4.5, 7.0, and 9.0 that had been exposed
to 70°C for 64 h were available for analysis. Oxytocin is a
basic peptide (pI 8.7), therefore, a PB-DS-PB capillary
coating was selected for CE-MS in combination with a low-
pH BGE. Under these conditions, the peptide and capillary
wall will be positively charged, and analyte adsorption will
be minimized. DS was used instead of PVS to prepare the
triple layer coating because it has been demonstrated that
DS provides superior coating stability and separation
efficiencies when applied as “in-between” polymeric layer
for peptide and protein analysis [44].
Separation conditions were optimized using the heat-
exposed solution of oxytocin (50 μg/mL) at pH 2.0. With a
BGE of 50 mM acetic acid (pH 3.0), the BPE obtained with
CE-MS revealed one main peak with a plate number of ca.
100,000. The mass spectrum of this peak comprised of
distinct signals at several m/z values, with the most intense
at m/z 1007.43, which agrees well with the mass of
protonated oxytocin. In order to optimize the CE perfor-
mance, the concentration acetic acid of the BGE (pH 3.0)
was varied between 50 and 1,000 mM. The plate number of
oxytocin increased with increasing BGE concentration
reaching an optimum (300,000) at 525 mM acetic acid.
Moreover, with increasing BGE concentrations, the CE
resolution improved, revealing additional, partially separat-
ed peaks. Acetic acid concentrations above 525 mM did not
result in higher plate numbers or better separation. Variation
of the pH (3.0–5.0) of a BGE of 525 mM acetic acid did not
result in improved separation. Acetic acid at 525 mM
(pH 3.0) was then selected as BGE for further analysis.
Under these conditions, migration time RSDs for oxytocin
were less than 1.4% (n=5), demonstrating the good
performance of the PB-DS-PB CE-TOF-MS system. No
additional peaks were observed indicating that the acidic
BGE did not cause oxytocin degradation within the time
frame of the CE analysis.
The BPE obtained upon CE-MS analysis of oxytocin
degraded at pH 2.0 showed five partially separated peaks.
The mass spectrum of the main peak (8.0 min) was
dominated by an intense signal at m/z 1007.43, whereas
the mass spectra of the degradation products migrating at
6.8 min and between 7.0–7.6 min, showed most abundant
signals at m/z 1009.39 and 1008.41, respectively. Using
these masses, extracted ion electropherograms (EIEs) were
constructed (Fig. 2a). The EIE of m/z 1007.43 represents
the unmodified oxytocin (single peak), whereas the EIE of
m/z 1008.41 exhibits three peaks. Considering the migra-
tion times of these three degradation products with respect
to oxytocin, they probably are less positively charged than
oxytocin. In combination with the gain in mass of about
1 Da compared with oxytocin, one can conclude that these
degradation products most likely are the result of single
deamidations of oxytocin. Indeed, oxytocin contains three
possible deamidation sites and apparently the three mono-
deamidated oxytocins can be separated by CE. The EIE of
m/z 1009.39 reveals the presence of bisdeamidated oxytocin
(Fig. 2a). As the peak shows an unresolved shoulder, we
concluded that at least two bisdeamidated variants have
been formed during heat degradation.
CE-MS of biopharmaceuticals using coated capillaries 299Oxytocin samples that were solved in phosphate buffer
of pH 4.5, 7.0, and 9.0 and exposed to 70°C for 64 h were
also analyzed with CE-MS, showing several degradation
products (Fig. 2b–d;T a b l e1). Clearly, deamidation is
most predominant at pH 2.0; the pH 4.5–9.0 samples show
only minor mono-deamidation and no bisdeamidation.
Interestingly, these samples show two degradation products
which comigrate with oxytocin. The mass increase of 31.95
and 63.91 Da with respect to oxytocin indicates that these
twoproductsmostlikelyaretheresultoftheadditionofone
a n dt w os u l f u ra t o m st ot h e i rmolecular structure. These
modifications do not induce a change of molecular charge
and therefore most probably are not separated. Although
unusual, trisulfide formation as a result of a β-elimination
processes caused by heat exposure has been reported [45].
The samples dissolved in buffer of pH 7.0 and 9.0 showed
another significant degradation product with m/z 975.40 at
a migration time of 6.8 min. From the isotope pattern, it
can be concluded that the compound is doubly protonated
and thus has a molecular weight of 1,948.8 Da. This gain
in mass with respect to oxytocin suggests the product to be
the result of a dimerization process involving loss of two
sulfur groups [41]. The exact mechanism of the formation
of this product is unclear.
Not much detailed information on oxytocin degradation
in therapeutic formulations is available in literature.
Oxytocin purity is generally assessed using liquid chroma-
tography (LC) with UV detection [46, 47], taking the
method described in the Ph. Eur. [48] as a starting point.
However, these methods do not allow identification of
the degradation products. Just recently, application of
reversed-phase (RP)LC-MS was reported for the assign-
ment of oxytocin degradation products [41]. With CE-
TOF-MS, we observed the same degradation products as
with the RPLC-MS method. The CE-MS analysis time
was considerably shorter (10 vs. 40 min); however, in
contrast to CE, RPLC allowed separation of degradation
products containing sulfur modifications such as tri- and
tetrasulfide bridges.
Recombinant human interferon-β-1a
The drug rhIFN-β is a 23-kDa N-glycosylated protein
(Asn
80), which is used for treatment of multiple sclerosis.
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Table 1 Compounds observed with CE-TOF-MS in heat-exposed oxytocin solutions of various pH
m/z (charge) Compound Relative peak area (%)
pH 2.0 pH 4.5 pH 7.0 pH 9.0
975.40 (2+) Oxytocin “dimer” ND 2.4 14.5 9.7
1007.43 (1+) Oxytocin 60.6 90.6 75.8 80.3
1008.41 (1+) Deamidated oxytocin 31.4 1.4 1.1 2.8
1009.39 (1+) Bisdeamidated oxytocin 8.0 ND ND ND
1039.37 (1+) “Trisulfide” oxytocin ND 4.8 7.0 5.7
1071.34 (1+) “Tetrasulfide” oxytocin ND 0.9 1.7 1.4
ND not detected
300 R. Haselberg et al.Over the past years, biosimilars of rhIFN-β have been
introduced onto the market. It has been demonstrated that
the glycosylation of rhIFN-β may significantly affect its
biological activity [49]. Therefore, establishment of the
glycoform heterogeneity among batches of rhIFN-β can be
of great importance. Moreover, glycoform profiling can be
a tool for characterizing and comparing rhIFN-β products,
including biosimilars. As protein glycosylation affects
charge and size of proteins, CE — with its charge-to-mass
separation mechanism — can be very useful for glycopro-
tein profiling. We studied whether rhIFN-β can be analyzed
with our CE-TOF-MS system and the information that can
be derived from the obtained data.
rhIFN-β is a basic protein (pI 9.6) and, therefore, to
avoid protein adsorption to the capillary wall, a PB-DS-PB
coated capillary was selected in combination with an acidic
BGE. Previously, we found a 50-mM acetic acid BGE
(pH 3.0) to be optimal for basic proteins [32]. The same
BGE appeared to provide good separation of rhIFN-β
glycoforms. The composition of the sheath liquid was
briefly optimized. Selection of an isopropanol content of
25% and a relatively high acetic acid concentration (0.5%)
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Fig. 3 CE-TOF-MS of rhIFN-β using a PB-DS-PB coated capillary. a
BPE (m/z 1,500–3,000). Deconvoluted mass spectrum obtained in the
apex of the peak migrating b at 9.1 min (asterisk) and c at 8.5 min
(double asterisks). d EIEs are at indicated m/z values (±0.2 Da);
assigned glycan structures are shown as insets. Symbols: closed circle,
hexose; closed upright triangle, fucose; open square, N-acetylhexos-
amine; open diamond, sialic acid. Conditions: BGE, 50 mM acetic
acid (pH 3.0); sheath liquid, isopropanol–water–acetic acid (25/75/0.5,
v/v/v)a t2μL/min. Sample preparation and other conditions, see
Materials and methods section
Table 2 Molecular mass, glycan composition, relative peak area, and migration time for rhIFN-β glycoforms as observed with CE-TOF-MS
Deconvoluted mass  22084 22375 22743  23032  23105  23398  23692  23765  24054  24424 
Glycan
a 
Relative peak area (%)
b  6.3 52.3 6.7  12.0  5.5  9.3  1.8  4.2  1.3  0.6 
Migration time (min)
c  9.5   9.1   8.9   8.5   8.6  8.5   8.1   8.3   8.0   7.9  
aSymbols: closed circle, hexose; closed upright triangle, fucose; open square, N-acetylhexosamine; open diamond, sialic acid
bTotal area of peaks observed in the respective EIE
cMigration time of the most intense peak observed in the respective EIE
CE-MS of biopharmaceuticals using coated capillaries 301appeared to be important to achieve good signals for rhIFN-
β. So, a sheath liquid of isopropanol–water–acetic acid (25/
75/0.5, v/v/v)a t2μL/min was applied. Typical migration
time RSDs for rhIFN-β under the selected conditions were
less than 1.6% (n=5).
The BPE obtained after CE-MS of rhIFN-β (450 μg/mL)
shows a distinct pattern of partially resolved bands (i.e.,
glycoforms) between 7.8 and 10.0 min (Fig. 3a). Figure 3b
shows the deconvoluted mass spectrum obtained in the apex
of the most intense peak (9.2 min), indicating a molecular
mass of 22,375 Da. Some minor signals of other glycoforms
with masses of 22,082 and 22,743 Da were also observed in
the spectrum. Deconvoluted spectra of other peaks in the
BPE also showed multiple compounds. For example, the
deconvoluted spectrum obtained for the peak at 8.5 min
shows at least five proteinaceous compounds (Fig. 3c). In
order to obtain a full picture of the number of different
glycoforms, deconvoluted mass spectra were constructed
with 0.1-min intervals in the range of 7.8 to 10.0 min. From
these mass spectra, a total of ten distinctive masses (Table 2)
representing different glycoforms could be determined;
unglycosylated rhIFN-β (20027 Da) was not detected. To
assign the glycoforms, mass differences between the ten
glycoforms were determined. Merely differences of 291 and
365 Da were found, indicating the loss or gain of either a
sialic acid unit or a hexose N-acetylhexosamine (HexHex-
NAc) unit, respectively (Fig. 3b, c). In addition, it has been
reported that the major glycoform rhIFN-β is a fucosy-
lated disialylated biantennary structure with four hexose
and five N-acetylhexosamine units [49, 50]. This glyco-
form, including the amino acid chain of rhIFN-β,h a sa
molecular weight of 22,375 Da. Thus, based on this
glycan structure and the calculated mass differences, the
most probable glycan composition of the other nine
glycoforms were derived (Table 2) .W eo b s e r v ef i v eo u t
of the six glycoforms described in the Ph. Eur. monograph
of IFN-β [51]. The nonsialylated isoform was not present
in the analyzed sample. On the other hand, our CE-MS
method revealed additional low-abundance glycoforms
with more sialic acid and HexHexNAc units than
described in the Ph. Eur. Our results also match well with
a previous report on ESI-MS of rhIFN-β [49], which
reported six out of the ten glycoforms we detected. This
underlines the importance of an efficient separation prior
to MS analysis in order to prevent signal suppression and
allow reliable and more detailed assignment.
For each assigned glycoform, an EIE was constructed
using the most abundant m/z value of the glycoform’s
respective charge envelope. Four selected EIEs are
depicted in Fig. 3d. From the EIEs, relative peak areas
for all ten detected glycoforms were obtained leading to a
quantitative glycoform distribution, assuming an equimo-
lar detector response per glycoform (Table 2). The glyco-
form with the lowest abundance was almost 1% in area
with respect to the most abundant isoform, but could still
be detected reliably. Relative abundance of glycoforms
may show useful for in-process and quality control of
rhIFN-β batches or to compare biosimilar products. From
the EIEs, it is clear that the overall migration time of the
glycoforms decreases with the degree of sialytion
(Fig. 3d). Differences in the number of HexHexNAc
groups present in a glycoform with the same number of
sialic acid groups only lead to a slight change of migration
time (Table 2). These observations are in good agreement
with results reported for CE-MS of other glycoproteins
[12, 52, 53]. It should be noted that, for each glycoform,
no well-defined peak but rather a reproducible pattern of
partially separated compounds was observed (Fig. 3d).
Degradation of sialic acid groups, which theoretically can
occur at low pH, is most unlikely during CE analysis as
this would require much harsher conditions (pH 2.0; 80°C) and
reaction times (>1 h) than applied (pH 3.0; 20°C; and <10 min)
[54]. Moreover, the obtained glycoform profile was highly
repeatable. Therefore, we speculate the peak clusters to be
glycan isomers, as also reported in the Ph. Eur. monograph
[51], with slightly different electrophoretic mobilities.
Concluding remarks
CE-TOF-MS methods applying on noncovalently coated
capillaries have been evaluated for biopharmaceutical
analysis. The acidic protein rhGH could be characterized
using a PB-PVS capillary coating and a medium-pH BGE,
whereas the PB-DS-PB coated capillary in combination
with a low-pH BGE appeared to be very suitable for the
analysis of the basic pharmaceuticals oxytocin and rhIFN-
β. Highly similar and/or related degradation products and
glycoforms could be assigned by the combination of CE
with TOF-MS. From the presented results, it can be
concluded that CE is especially suitable for the separation
of protein modifications leading to charge differences. For
example, degradation products as result of deamidation or
sulfonic acid formation were efficiently resolved from the
parent compound. Also, protein glycoforms which differ in
number of sialic acid groups could be separated. In case
that modifications did not affect the overall protein charge,
the high mass resolution and accuracy of the TOF-MS still
allowed assignment of components. So, we believe there is
strong potential for CE-TOF-MS systems using noncova-
lent coated capillaries for the purity and stability analysis of
biopharmaceuticals. Moreover, the CE-MS systems seem
very useful for highly specific glycoform profiling. Cur-
rently, we are studying the usefulness of CE-TOF-MS
systems for the characterization and comparison of bio-
similars.
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